Isis Pharmaceuticals (NASDAQ:ISIS) announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c (HbA1c) of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) net profit margin is -69.60% and weekly performance is 10.63%. On last trading day company shares ended up $33.63. Analysts mean target price for the company is $43.56. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) distance from 50-day simple moving average (SMA50) is 10.79%.
Verint Systems Inc. (NASDAQ:VRNT) announced that it has agreed to sell, at a public offering price of $47.75 per share, an aggregate of 5,000,000 shares of its common stock. Verint Systems Inc. (NASDAQ:VRNT) shares advanced 1.95% in last trading session and ended the day on $49.22. VRNT Gross Margin is 65.00% and its return on assets is 4.80%. Verint Systems Inc. (NASDAQ:VRNT) quarterly performance is 7.80%.
Alliance Data Systems (NYSE:ADS) had its price target increased by RBC Capital from $284.00 to $288.00. They currently have an outperform rating on the stock. Alliance Data Systems Corporation (NYSE:ADS) shares moved up 2.52% in last trading session and was closed at $269.82, while trading in range of $263.25 – $269.89. Alliance Data Systems Corporation (NYSE:ADS) year to date (YTD) performance is 2.62%.
Trade-Ideas LLC identified Novo Nordisk A/S (ADR) (NYSE:NVO) as a pre-market mover with heavy volume candidate. TheStreet Quant Ratings rates Novo Nordisk A/S as a buy. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and expanding profit margins. Novo Nordisk A/S (ADR) (NYSE:NVO) ended the last trading day at $4.76. Company weekly volatility is calculated as 1.01% and price to cash ratio as 101.11. Novo Nordisk A/S (ADR) (NYSE:NVO) showed a positive weekly performance of 2.80%.
The NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) announced the results of the semi-annual evaluation of the NASDAQ OMX ABA Community Bank Index (Nasdaq:ABQI), which will become effective prior to market open on Monday, June 23, 2014. NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) net profit margin is 14.50% and weekly performance is -1.95%. On last trading day company shares ended up $36.73. Analysts mean target price for the company is $41.54. NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) distance from 50-day simple moving average (SMA50) is 1.25%.